559 related articles for article (PubMed ID: 2581135)
21. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Pifl C; Schingnitz G; Hornykiewicz O
Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
[TBL] [Abstract][Full Text] [Related]
22. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
Pifl C; Schingnitz G; Hornykiewicz O
Neurosci Lett; 1988 Oct; 92(2):228-33. PubMed ID: 3263594
[TBL] [Abstract][Full Text] [Related]
23. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
[TBL] [Abstract][Full Text] [Related]
24. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys.
Chiueh CC; Burns RS; Markey SP; Jacobowitz DM; Kopin IJ
Life Sci; 1985 Jan; 36(3):213-8. PubMed ID: 3871241
[TBL] [Abstract][Full Text] [Related]
25. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1).
Sheng JG; Xu DL; Yu HZ; Xu XR; Tang QM
Life Sci; 1987 May; 40(20):2007-10. PubMed ID: 2437428
[TBL] [Abstract][Full Text] [Related]
26. Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Collins MA; Neafsey EJ
Neurosci Lett; 1985 Apr; 55(2):179-84. PubMed ID: 2582318
[TBL] [Abstract][Full Text] [Related]
27. Parkinsonism induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cats: behavioral, biochemical and pathological studies.
Chen S; Zhou X; Xu D; Tang Q; Xu X
Chin Med Sci J; 1993 Dec; 8(4):223-6. PubMed ID: 8032069
[TBL] [Abstract][Full Text] [Related]
28. MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.
Langston JW; Langston EB; Irwin I
Acta Neurol Scand Suppl; 1984; 100():49-54. PubMed ID: 6333134
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent.
Zimmerman DM; Cantrell BE; Reel JK; Hemrick-Luecke SK; Fuller RW
J Med Chem; 1986 Aug; 29(8):1517-20. PubMed ID: 3488406
[TBL] [Abstract][Full Text] [Related]
30. Effect of MPTP-induced parkinsonism in monkeys on the urinary excretion of HVA and MHPG during debrisoquin administration.
Kopin IJ; Bankiewicz K; Harvey-White J
Life Sci; 1988; 43(2):133-41. PubMed ID: 3260652
[TBL] [Abstract][Full Text] [Related]
31. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.
Elsworth JD; Deutch AY; Redmond DE; Taylor JR; Sladek JR; Roth RH
Neuroscience; 1989; 33(2):323-31. PubMed ID: 2622529
[TBL] [Abstract][Full Text] [Related]
32. Assessment of metabolic changes in the striatum of a MPTP-intoxicated canine model: in vivo ¹H-MRS study of an animal model for Parkinson's disease.
Choi CB; Kim SY; Lee SH; Jahng GH; Kim HY; Choe BY; Ryu KN; Yang DM; Yim SV; Choi WS
Magn Reson Imaging; 2011 Jan; 29(1):32-9. PubMed ID: 20980117
[TBL] [Abstract][Full Text] [Related]
33. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ
Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654
[TBL] [Abstract][Full Text] [Related]
34. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Burns RS; Chiueh CC; Markey SP; Ebert MH; Jacobowitz DM; Kopin IJ
Proc Natl Acad Sci U S A; 1983 Jul; 80(14):4546-50. PubMed ID: 6192438
[TBL] [Abstract][Full Text] [Related]
35. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
Bradbury AJ; Costall B; Domeney AM; Testa B; Jenner PG; Marsden CD; Naylor RJ
Neurosci Lett; 1985 Oct; 61(1-2):121-6. PubMed ID: 2417166
[TBL] [Abstract][Full Text] [Related]
36. Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology, and biochemistry.
Schneider JS; Yuwiler A; Markham CH
Exp Neurol; 1986 Feb; 91(2):293-307. PubMed ID: 3484707
[TBL] [Abstract][Full Text] [Related]
37. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Russ H; Mihatsch W; Gerlach M; Riederer P; Przuntek H
Neurosci Lett; 1991 Feb; 123(1):115-8. PubMed ID: 1712088
[TBL] [Abstract][Full Text] [Related]
38. Reduction of biogenic amine levels in the Rett syndrome.
Zoghbi HY; Percy AK; Glaze DG; Butler IJ; Riccardi VM
N Engl J Med; 1985 Oct; 313(15):921-4. PubMed ID: 2412119
[TBL] [Abstract][Full Text] [Related]
39. Modeling neurodegenerative diseases in vivo review.
von Bohlen Und Halbach O
Neurodegener Dis; 2005; 2(6):313-20. PubMed ID: 16909014
[TBL] [Abstract][Full Text] [Related]
40. Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP.
Kopin IJ; Bankiewicz KS; Harvey-White J
Neuropsychopharmacology; 1988 May; 1(2):119-25. PubMed ID: 3266957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
